de Bono, Johann S. http://orcid.org/0000-0002-2034-595X
Guo, Christina
Gurel, Bora
De Marzo, Angelo M.
Sfanos, Karen S.
Mani, Ram S.
Gil, Jesús http://orcid.org/0000-0002-4303-6260
Drake, Charles G.
Alimonti, Andrea http://orcid.org/0000-0002-9362-2313
Article History
Accepted: 24 April 2020
First Online: 16 June 2020
Competing interests
: J.S.d.B., B.G. and C.G. are employed by the Institute of Cancer Research, which has commercial interests in abiraterone, in the use of PARP inhibitors in DNA repair-defective cancers and in IL-23 driving AR signalling in prostate cancer. J.S.d.B. has served on advisory boards for companies, including AstraZeneca (AZ), Astellas, Bayer, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Genentech/Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme (MSD), Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology and Taiho. His institution has received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi Sankyo, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Pfizer, Sanofi Aventis, Sierra Oncology and Taiho. He has been the CI/PI of many industry-sponsored clinical trials. A.M.D.M. has served as a sponsored research recipient from Janssen R&D and Myriad Genetics, and currently he serves as a consultant for Cepheid Inc. J.G. owns equity and has acted as a consultant for Unity Biotechnology and Geras Bio. J.G. is an inventor in a Medical Research Council patent related to senolytic therapies (PCT/GB2018/051437). C.G.D. has served on advisory boards for AZ Medimmune, Bristol Myers Squibb (BMS), F-Star, Genocea, Janssen, Merck, Pfizer, Pierre Fabre, Genentech/Roche and Sanofi Aventis. His institution holds AZ Medimmune, BMS and Janssen patents, and he has interests in Harpoon, Kleo, Shattuck Labs, Tizona and Werewolf. A.A. is a cofounder and shareholder of Oncosence; he is inventor of the following patents: WO2019142095A1, WO2019142097A1, WO2019180636A1 and US20200095314A1. No relevant conflicts of interest were disclosed by other authors.